Publicacións en colaboración con investigadores/as de Hospital Universitari Sant Joan de Reus (17)

2024

  1. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  2. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study

    Future oncology (London, England), Vol. 18, Núm. 35, pp. 3913-3927

2021

  1. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871

  2. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Metastatic colorectal cancer. First line therapy for unresectable disease

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-10

2017

  1. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

    European Journal of Cancer, Vol. 82, pp. 16-24

2016

  1. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

    Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579

2013

  1. Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer

    Breast Cancer Research and Treatment, Vol. 132, Núm. 1, pp. 307-315

  2. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?

    Breast, Vol. 21, Núm. 6, pp. 755-760

2011

  1. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry

    Breast Cancer Research and Treatment, Vol. 128, Núm. 2, pp. 573-579

2009

  1. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort

    Human Reproduction, Vol. 24, Núm. 4, pp. 1000-1006

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2005

  1. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438

2004

  1. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: Preliminary results from a phase II trial

    Seminars in Oncology, Vol. 31, Núm. 2 SUPPL. 5, pp. 20-24